BioPorto Q1 2026 adjusted EBITDA loss narrows 36% to DKK 17.9 million; revenue rises 23% to DKK 9.4 million

  • BioPorto reported Q1 2026 revenue rising 23% to DKK 9.4 million.
  • Total NGAL revenue climbed 33% to DKK 6 million, driven by higher U.S. NGAL Research Use Only sales.
  • Adjusted EBITDA loss narrowed 36% to DKK 17.9 million, while cash fell to DKK 39.6 million as of March 31.
  • The group filed an FDA pre-submission package for adult urine NGAL, onboarded four new U.S. university hospitals to bring the total to 48, and maintained 2026 guidance for revenue of DKK 38-48 million with adjusted EBITDA loss of DKK 58-68 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioPorto A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210255OMX_____CNEWS_EN_GNW1001183212_en) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.